抗驚厥藥市場：按藥物類別、給藥途徑、適應症、分銷渠道、地區 - 規模、份額、前景和機會分析，2022-2030 年

抗驚厥藥是一類用於治療癲癇發作的藥物。 由於許多抗驚厥藥傾向於充當情緒穩定劑，因此它們也越來越多地用於治療神經性疼痛、雙相情感障礙和邊緣型人格障礙。 加巴噴丁、卡馬西平和丙戊酸等抗驚厥藥通過阻斷細胞神經元水平的鈉（丙戊酸和加巴噴丁類）或鈣（卡馬西平和奧卡西平）通道來緩解慢性疼痛。據信 這抑制了自發的電活動並恢復了超敏傷害性神經元去極化的正常閾值，而不影響正常的神經傳導。

這些藥物對患有神經性疼痛和情緒障礙的患者最有效。 抗驚厥藥分為第一代（經典）和第二代藥物。 第二代抗驚厥藥通常比傳統抗驚厥藥耐受性更好，治療窗更廣。 藥物的選擇取決於癲癇發作的類型。 局灶性發作的一線藥物是拉莫三秦或左乙拉西坦，丙戊酸鹽用於全身性發作。 所有抗驚厥藥都有劑量依賴性中樞神經系統副作用（如嗜睡和噁心），但選擇性藥物有其他副作用（如苯妥英引起的牙齦增生）。

市場動態

預計癲癇病患病率的增加將推動預測期內的市場增長。 例如，根據世界衛生組織的數據，截至 2022 年 2 月，癲癇將成為全球最常見的神經系統疾病之一，影響約 5000 萬人。 近 80% 的癲癇患者生活在低收入和中等收入國家。 根據同一份文件，估計如果診斷和治療得當，多達 70% 的癲癇患者可以無癲癇發作地生活。

這項研究的主要特點

• 本報告對以 2021 年為基準年的預測期 (2022-2030) 的全球抗驚厥藥市場、市場規模和復合年增長率 (CAGR%) 進行了深入分析。
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
• 根據公司亮點、按類型劃分的產品組合、主要亮點、財務業績和市場戰略等參數，介紹全球抗驚厥藥市場主要參與者的概況。
• 本研究涵蓋的主要公司包括 Novartis AG、GSK plc.、Johnson & Johnson、Teva Pharmaceutical Industries Ltd.、Pfizer, Inc.、Zogenix、Dr. Reddy's Laboratories Ltd.、Alkem Labs、SK BIOPHARMACEUTICALS、Eisai Co. , Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and博士倫健康公司
• 這份報告中的見解將使企業營銷人員和高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。.
• 《全球抗驚厥藥市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球抗驚厥藥市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按藥物類別
  • 按給藥途徑劃分的市場概況
  • 市場概況：按指示
  • 市場概況：按分銷渠道
  • 市場概況：按地區
  • 市場機會地圖

第 3 章抗驚厥藥的全球市場洞察

• 司機
• 約束因素
• 市場機會
• 影響分析
• 管道分析
• 害蟲分析
• 主要發展狀況
• 監管情景
• 合併/收購場景
• 定價分析
• 品牌映射

第 4 章全球抗驚厥藥市場 - 冠狀病毒 (COVID-19) 大流行的影響

• COVID-19 的流行病學特徵
• 對供需的影響
• 對臨床試驗的影響

第 5 章全球抗驚厥藥市場：按藥物類別，2017-2030

• 巴比妥類藥物
• 苯二氮卓類
• 芳香烯丙醇
• 甲□胺
• 三秦
• AMPA 受體拮抗劑
• 氨基甲酸酯
• 乙內□尿
• 脂肪酸衍生物
• GABA 類似物
• 丙丙□胺
• 其他（丙酸鹽、噁唑烷二酮等）

第 6 章全球抗驚厥藥市場：按給藥途徑，2017-2030

• 腸內管理
• 父母代理人

第 7 章全球抗驚厥藥市場：按適應症分類，2017-2030

• 癲癇症
• 神經性疼痛
• 焦慮症
• 纖維肌痛
• 躁鬱症
• 其他（邊緣性人格障礙等）

第 8 章全球抗驚厥藥市場：按分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 9 章全球抗驚厥藥市場：地區，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 德國
• 英國
• 法國
• 意大利
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 澳大利亞
• 韓國
• 東盟
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 南非
• 中非
• 北非

第十章公司簡介

• 諾華公司
  • 公司亮點
  • 產品組合
  • 主要亮點
  • 財務業績
  • 市場策略
• GSK plc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• Zogenix
• DR. Reddy's Laboratories Ltd.
• Alkem Labs
• SK BIOPHARMACEUTICALS
• Eisai Co., Ltd
• Angelini S.p.a.
• Sun Pharmaceutical Industries Ltd.
• UCB S.A.
• Unichem Laboratories
• Jazz Pharmaceuticals, Inc.
• Neuropathix, Inc.
• Xenon Pharmaceuticals, Inc.
• SK Life Science, Inc.
• Sumitomo Pharma Co., Ltd
• Bausch Health Companies Inc.

第 11 章章節

• 調查方法
• 關於出版商

Anticonvulsants are a broad class of drugs used to treat epileptic seizures. Since many anticonvulsants tend to operate as mood stabilizers, they are also being used more frequently to treat neuropathic pain, bipolar disorder, and borderline personality disorder. Anticonvulsants, including gabapentin, carbamazepine, and valproic acid, are believed to alleviate chronic pain by obstructing sodium (valproate and the gabapentanoids) or calcium (carbamazepine and Oxcarbazepine) channels at the cellular neuronal level. This suppresses spontaneous electrical activity and restores the normal threshold to depolarization of hypersensitive nociceptive neurons without affecting normal nerve conduction.

Patients with neuropathic pain and mood disorders benefit most from these drugs. Anticonvulsant drugs are classified as either first-generation (classic) agents or second-generation agents. Second-generation anticonvulsants are usually better tolerated and have a broader therapeutic range than classic anticonvulsant drugs. The choice of drug is guided by the type of seizure. First-line treatment for focal seizures includes lamotrigine or levetiracetam, while valproate is used for generalized seizures. While all anticonvulsants have dose-dependent side effects on the central nervous system (e.g., somnolence, nausea), select agents also have other side effects (e.g., gingival hyperplasia caused by phenytoin).

Market Dynamics

Increasing prevalence of epilepsy is expected to propel the market growth over the forecast period. For instance, according to the World Health Organization, in February 2022, epilepsy is one of the most common neurological diseases globally, which affects around 50 million people. Nearly 80% of people with epilepsy live in low- and middle-income countries. According to the same source, it is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.

Key features of the study:

• This report provides an in-depth analysis of the global anticonvulsant drugs market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anticonvulsant drugs market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include Novartis AG, GSK plc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK BIOPHARMACEUTICALS, Eisai Co., Ltd, Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A., Unichem Laboratories, Jazz Pharmaceuticals, Inc., Neuropathix, Inc., Xenon Pharmaceuticals, Inc., SK Life Science, Inc., Sumitomo Pharma Co., Ltd, and Bausch Health Companies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global anticonvulsant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticonvulsant drugs market

Detailed Segmentation:

• Global Anticonvulsant Drugs Market, By Drug Class:
  • Barbiturates
  • Benzodiazepines
  • Aromatic allylic alcohols
  • Carboxamides
  • Triazine
  • AMPA receptor antagonists
  • Carbamate
  • Hydantoin
  • Fatty Acid Derivative
  • GABA analogs
  • Valproylamides
  • Others (Propionates, Oxazolidinediones, etc.)
• Global Anticonvulsant Drugs Market, By Route of Administration:
  • Enteral
  • Parenteral
• Global Anticonvulsant Drugs Market, By Indication:
  • Epilepsy
  • Neuropathic pain
  • Anxiety
  • Fibromyalgia
  • Bipolar Disorder
  • Others (Borderline personality disorder, etc.)
• Global Anticonvulsant Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Anticonvulsant Drugs Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Novartis AG
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • GSK plc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Zogenix
  • Dr. Reddy's Laboratories Ltd.
  • Alkem Labs
  • SK BIOPHARMACEUTICALS
  • Eisai Co., Ltd
  • Angelini S.p.a.
  • Sun Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Unichem Laboratories
  • Jazz Pharmaceuticals, Inc.
  • Neuropathix, Inc.
  • Xenon Pharmaceuticals, Inc.
  • SK Life Science, Inc.
  • Sumitomo Pharma Co., Ltd
  • Bausch Health Companies Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Indication
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
  • Market Opportunity Map

3. Global Anticonvulsant Drugs Market Insights

• Drivers
• Restraints
• Opportunity
• Impact Analysis
• Pipeline Analysis
• PEST Analysis
• Key Developments
• Regulatory Scenario
• Merger & Acquisition Scenario
• Pricing Analysis
• Brand Mapping

4. Global Anticonvulsant Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Epidemiology
• Impact On Supply And Demand
• Impact on Clinical Trials

5. Global Anticonvulsant Drugs Market, By Drug Class, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Barbiturates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Aromatic allylic alcohols
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Carboxamides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Triazine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• AMPA receptor antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Carbamate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Hydantoin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Fatty Acid Derivative
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• GABA analogs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Valproylamides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Others (Propionates, Oxazolidinediones, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

6. Global Anticonvulsant Drugs Market, By Route of Administration, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Enteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

7. Global Anticonvulsant Drugs Market, By Indication, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Neuropathic pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Anxiety
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Fibromyalgia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Bipolar Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Others (Borderline personality disorder, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

8. Global Anticonvulsant Drugs Market, By Distribution Channel, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

9. Global Anticonvulsant Drugs Market, By Region, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Region at Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017-2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (US$ Mn)
  • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017-2030, (US$ Million)
• South Africa
• Central Africa
• North Africa

10. Company Profiles

• Novartis AG*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GSK plc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• Zogenix
• DR. Reddy's Laboratories Ltd.
• Alkem Labs
• SK BIOPHARMACEUTICALS
• Eisai Co., Ltd
• Angelini S.p.a.
• Sun Pharmaceutical Industries Ltd.
• UCB S.A.
• Unichem Laboratories
• Jazz Pharmaceuticals, Inc.
• Neuropathix, Inc.
• Xenon Pharmaceuticals, Inc.
• SK Life Science, Inc.
• Sumitomo Pharma Co., Ltd
• Bausch Health Companies Inc.

11. Section

• Research Methodology
• About us